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ESRD patient mortality with adjustment for comorbid conditions in
Lombardy (Italy) versus the United States. The present study evaluated
end-stage renal disease (ESRD) patient survival in Lombardy, Italy, and
the United States (U.S.) using data from two registries, the Lombardy
Dialysis and Transplant Registry (RLDT) and the U.S. Renal Data System
(USRDS), respectively. For this purpose, 4,196 white patients (2,900 from
the USRDS Case Mix Severity Study and all 1296 from RLDT) who
started renal replacement therapy in 1986 and 1987 were studied. Com-
pared to Lombardy patients, those in the USA were significantly older
(mean age 59.9 16.4 vs. 55.9 14.7 years), had a lower proportion of
males (53.7 vs. 62.1%), a greater proportion with diabetic nephropathy
(29.9 vs. 9.7%) and a significantly greater proportion of patients with the
recorded comorbid conditions (heart disease, peripheral vascular disease,
cirrhosis, cachexia, malignancy). U.S. patients were less frequently treated
with peritoneal dialysis (PD) by day 30 of ESRD (21.2 vs. 30.7). Survival
was compared in the Cox proportional hazard regression model, using age,
sex, comorbid conditions and early modality of treatment as explanatory
covariates. Overall, 48% of the 4196 patients died during the 48 to 72
months follow-up to 12/31/91. Per 100 patient-years the gross death rate
for USRDS patients was 28.7 compared to 13.0 of RLDT patients. The
unadjusted death relative risk for RLDT was 0.439, that is, 56% lower
death rate compared to USRDS patients. Age, sex, diabetic status, each of
the recorded comorbid conditions and treatment modality were signifi-
cantly related to survival and included in the model. The Cox cumulative
survival adjusted for all these explanatory covariates survival was for U.S.
patients 84.4% at one year, 67.0% at two years and 33.4% at five years,
and for RLDT patients 88.3% at one year, 75.9% at two years and 45.9%
at five years. The relative mortality risk (RR) for the patients treated in
Lombardy adjusted for all the reported covariates was 29% lower than for
US patients (RR = 0.71; P < 0.0001). This comparative risk varied
significantly by age (P < 0.0001) and was 65 percent lower for Lombardy
compared to U.S. patients in the age range 25 to 44 years (RR = 0.35) and
about 20% lower for patients over age 65 years (RR = 0.80). This relative
risk was mainly related to hemodialysis and was not statistically significant
for PD patients. The observed lower mortality risk in Lombardy was less
pronounced when adjusted for demographic and comorbid covariates, but
was still large and therefore suggests the need for further studies regarding
treatment related factors and unmeasured patient factors, particularly in
hemodialysis patients.
The survival of end-stage renal disease (ESRD) in the U.S.
patients has been reported to be lower than that of Japan and the
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European Dialysis and Transplant Association (EDTA) countries
for most adult age groups, both for diabetic and non-diabetic
patients [1, 2]. The aim of these international comparisons is to
evaluate factors which may explain the differences such as dialysis
technology on the one hand, such as short versus long dialysis
treatment times, high versus low dialysis dose, re-use versus
non-re-use of dialyzers and, on the other hand, patient factors. It
is well known that U.S. patients are older [3] and probably have
more comorbid conditions than European and Japanese patients.
Moreover, the relatively high transplantation rate in the U.S.
removes from dialysis more young and healthy patients than in
countries with lower rates of transplantation. Finally, one needs to
take into account that the life expectancy may be different not
only between populations of different countries, but also between
whites and blacks within the U.S. Therefore, these studies show-
ing that survival of ESRD patients was best in Japan, second-best
in Europe, and lowest in the U.S. suggest the need for consider-
ation of many factors including differences in dialysis technology.
This study compared ESRD patient samples of two Registries,
United States Renal Data System (USRDS) and Lombardy
Dialysis and Transplant Registry (RLDT). In order to improve
the comparability of the patients only U.S. whites were consid-
ered; the expectation of life of the U.S. white population [4] (irt
1990, 72.7 years for males and 79.4 for females) is quite similar to
that of the Lombardy population [5] (1986 to 1990, 73.2 years for
males, 79.7 years for females). Statistical adjustment included not
only the background variables (sex, age at onset of ESRD) but
also underlying renal disease and comorbid conditions. The
samples were compared as a whole, and also taking into account
interaction between age and registry. Analysis of the elderly group
of patients who rarely receive a renal transplant minimizes the
effects of healthier patients being selected for renal transplanta-
tion more frequently in the U.S. than in Lombardy.
Methods
Data collection
The data used in this analysis come from the Case Mix Severity
Special Study of the USRDS [6] and from the RLDT, regarding
patients who started the renal replacement therapy for ESRD
during 1986 to 1987. The USRDS data were abstracted during
1989 by the 18 ESRD Networks under contract with the Health
Care Financing Administration (HCFA) using a data collection
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Variable Reference
USRDS
N = 2900
RLDT
N = 1296
P
value
Age years (mean
SD)
59.9 16.4 55.9 14.7 0.001
Male Female 1557(53.7%) 805 (62.1%) 0.001
Diabetes Non-diabetes 867 (29.9%) 126 (9.7%) 0.001
Heart disease Absent 1763 (60.8%) 161 (12.4%) 0.001
Vascular disease Absent 849 (29.3%) 214 (16.5%) 0.001
Cirrhosis Absent 58 (2.0%) 20 (1.5%) 0.3 11
Cachexia Absent 398 (13.7%) 23 (1.8%) 0.001
Malignancy Absent 313 (10.8%) 86 (6.6%) 0.001
Peritoneal dialysis Hemodialysis 616(21.2%) 398(30.7%) 0.001
form developed and tested by the USRDS Coordinating Center,
NIDDK, HCFA and the ESRD Networks. The sample of 5,281
incident patients was drawn from 291 dialysis units, using a
national, two-stage randomized sample design based on the last
two digits of the patients' social security numbers. A detailed
description of the sampling methodology has already been re-
ported [71. The data collected on the abstraction form were
supplemented with data from the USRDS database, which con-
tains longitudinal data on all Medicare ESRD patients in the U.S.
from 1977 to the present. Most of these data are derived from the
HCFA Program Management and Medical Information System.
USRDS data were based on a May 1993 update of HCFA file
sources, which were used to determine survival and transplant
status up to December 31, 1991.
The Lombardy Dialysis and Transplant Registry was begun in
1982 under the aegis of the Lombardy Regional Section of the
Italian Society of Nephrology and the Regional Health Depart-
ment, with the aim of creating an official registry capable of
collecting all the main clinical data concerning ESRD patients in
Lombardy Nephrology units. The data are collected at the end of
each year (100% response rate). The 1372 incident patients
during 1986 to 1987 were drawn from all 44 Lombardy dialysis
units. A detailed study on the Lombardy 1983 to 1992 dialysis and
transplantation results has been reported [8].
The comparison was limited to the white patients who started
RRT on dialysis. To avoid the inclusion of acute renal failure
patients, those patients who died in the first 30 days of treatment
were excluded from the analysis.
Statistical methods
Cox proportional hazard regression models [9] were used to
evaluate the mortality of USA white relative to Lombardy ESRD
patients. The independent variables tested for adjusting the death
rate in the U.S. patients relative to the death rate in the Lombardy
patients were age at the baseline, sex, underlying disease (non-
diabetic or diabetic ncphropathy), comorbid conditions collected
from both Registries (heart disease, such as congestive heart
failure and coronary artery disease; cerebrovascular disease, such
as stroke or TIA; peripheral vascular disease; neoplasm; cirrhosis;
and cachexia) and the modality of treatment. Two models were
used to evaluate the relative risk by registry for all RRT patients
(model A) and for dialysis patients (model B). In model A, patient
survival times were censored only at the time of loss to follow-up
(such as moving out of Lombardy) and at December 31, 1991. In
model B, patients were classified as being on hemodialysis, or on
peritoneal dialysis according to their modality at one month since
the onset of ESRD, and patient survival was tracked on that
treatment modality. Patient's survival times were censored at the
earliest of first renal transplant, two months after the first change
of dialysis treatment, loss of follow-up or on December 31, 1991.
All deaths that occurred within the first two months after a change
in dialytic modality were included as deaths on the first treatment.
In both analyses, patient survival was analyzed considering death
from any cause as the event. To identify the set of explanatory
variables that have the potential for being included in the linear
component of the model, the strategy for model selection sug-
gested by Collett [10] was adopted.
Results
Patient characteristics
There were 4,196 patients who satisfied the study entry criteria,
2,900 from the Case Mix Severity Special Study of the USRDS
and 1,296 from RLDT (Table 1). The mean age was (± SD) 59.9
16.4 years for patients of USRDS sample which was four years
older than that of RLDT (55.9 14.7 years). Both registries
showed an excess of male patients, which was greater in RLDT
(62 vs. 54%). USRDS sample showed a significantly larger
proportion of patients with diabetes (30 vs. 10%). At onset of
ESRD heart disease was the most frequent comorbid conditiort
(46% overall). The USRDS sample showed a fivefold greater
proportion of patients with heart disease than the RLDT. Vascu-
lar disease, the second most frequent comorbid condition (25%),
was nearly twice as common in the USRDS sample than in the
RLDT. Almost 2% of the patients were malnourished in the
RLDT versus 13.7% in the USRDS. Cirrhosis was not very
frequently recorded in both the registries (about 2%). Almost
11% of patients in the USRDS were affected by malignancy at the
start of ESRD compared to 6.6% in the RLDT. The proportion
Table 1. Patient characteristics stratified according to the original
source data 1.0
0.9
0.8
Ca>
>
0.6
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. 0.5
t-Test for continuous variable, univariate chi-square test for categori-
cal variables
0 12 24 36 48 60 72
Time, months
Fig. 1. Cox adjusted survival curves adjusted to the average age for patients
on dialysis in Lombardy and the US. Symbols are: (—) RLDT,N = 1296;
( ) USRDS, N = 2900.
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Variable Reference
Relative death rate
mean (95% CI.) P value
Age per year 1.043 (1.039—1.047) > 0.0001
Male Female 1.116 (1.021—1.219) 0.0157
Diabetes non-Diabetes 1.499 (1.351—1.663) > 0.0001
Heart disease Absent 1.405 (1.264—1.562) > 0.0001
Vascular disease Absent 1.344 (1.220—1.480) > 0.0001
Cirrhosis Absent 1.346 (1.030—1.758) 0.0296
Cachexia Absent 1.359 (1.196-1.545) > 0.0001
Malignancy Absent 1.466 (1.289—1.667) > 0.0001
Peritoneal dialysis Hemodialysis 1.344 (1.205—1.499) > 0.0001
RLDT USRDS 0.712 (0.628—0.806) > 0.0001
treated with peritoneal dialysis was higher in Lombardy (30.7%)
than in the USRDS (21.2%).
Patient survival
Forty-eight percent of the 4196 patients died. The unadjusted
death rate of USRDS patients was 28.7 per 100 patient year
compared to 13.0 per 100 patient year for RLDT patients. The
unadjusted relative mortality risk of RLDT compared to USRDS
patients was 0.439, indicating a 56% lower death rate in Lom-
bardy. Figure 1 shows the Cox adjusted curves adjusted to the
average age for patients on renal replacement therapy (RRT) in
U.S. and in Lombardy. The cumulative survival of the patients
undergoing dialysis in the calendar years 1986 to 87 (modality on
day 30) in U.S. was 82.0% at one year, 63.4% at two years and
30.7% at five years; that of RLDT patients was 89.6% at one year,
78.7% at two years and 52.6% at five years.
According to model A, the relative death rate for all RRT was
adjusted for the demographic and comorbid factors of Table 2 (all
significantly related to mortality, data not shown), but not for
modality of treatment. The adjusted relative death rate (RR) was
21 percent lower in Lombardy patients than for those in the U.S.
(RR = 0.789, 95% confidence interval 0.705 to 0.882). According
to model B for dialysis patients (censoring at transplant or 60 days
after change in dialytic modality), the result based on the Cox
proportional hazard model (without interaction) are given in
Table 2. The adjusted mortality risk for all patients on dialysis was
higher for older patients (RR = 1.043 per year; P < 0.000 1). The
death risk for males was 11.6 percent higher than for females
(RR = 1.116; P 0.016). Compared with non-diabetics, the death
rates of diabetic patients were 1.5 times higher (P < 0.0001).
Adjusting for all covariates listed in Table 2, the death rate for
the patients with heart disease was about 40% (P < 0.0001) higher
than for patients without this condition. The risk of mortality was
increased for those with vascular disease by 34% (P < 0.0001),
those with cirrhosis by 35% (P = 0.03), those with cachexia by
36% (P < 0.0001) and those with malignancy by 47% (P < 0.0001)
than for the patients without the respective reported comorbid
condition while adjusting for all other factors in Table 2. The
adjusted death rate for the patients on peritoneal dialysis was
overall 34% greater (P < 0.0001) than that of the patients on
hemodialysis (Table 2).
The interaction term between modality of treatment and reg-
istry was significantly related to mortality (P = 0.004), indicating
that comparisons between registries were different by modality.
The adjusted death rate for the patients on peritoneal dialysis in
HD Modality
Fig. 2. Relative mortality risk adjusted for demographic and comorbid
factors for peritoneal and hemodialysis patients for Lombardy using US
hemodialysis patients as the reference group (that is, RR = 1.00). Symbols
are: (•) USRDS; (LI) Lombardy. HD: RR = 0.64, P < 0.01. PD: RR =
0.90, P < 0.24 for Lombardy vs. U.S. *p = 0.03 vs. U.S. hemodialysis;
**p < 0.01 vs. Lombardy hemodialysis.
Lombardy was not statistically different from that of the patients
on peritoneal dialysis in the U.S. (RR = 0.90). The adjusted death
rate for the patients on hemodialysis in Lombardy was 36% lower
than that of the patients on hemodialysis in the U.S. (RR =0.635,
95% confidence interval 0.547 to 0.737). Results for adjusted
comparisons with U.S. hemodialysis patients are shown in Figure
2. Stratifying the patients into two strata by age (cut point 60
years), the interaction term between modality of treatment and
registry were significantly related to mortality (P = 0.011) only in
the subgroup of patients aged less than 60. In the patients on
peritoneal dialysis of this age-group, the relative risk of mortality
for patients treated in Lombardy was not statistically different
than that of the patients treated in the U.S. (RR = 0.945, 95%
confidence interval 0.55 to 1.62). In the patients with the same age
on hemodialysis, the relative risk of mortality for patients treated
in Lombardy was 36% lower than that of the patients on
hemodialysis in the U.S. (RR = 0.659, 95% confidence interval
0.49 to 0.88.
Fig. 3 shows the Cox adjusted curves adjusted to the average
demographic and comorbid characteristic of all patients on dial-
ysis in U.S. and in Lombardy. The adjusted cumulative survival in
U.S. was 84.4% at one year, 67.0% at two years and 33.4% at five
years, that of RLDT patients was 88.3% at one year, 75.9% at two
years and 45.9% at five years. The relative mortality risk was 29%
lower in Lombardy dialysis patients than for those in the U.S.
(RR = 0.712, P < 0.0001). The interaction term between age and
registry were significantly related to mortality (P < 0.0001).
Figure 4 shows the relative mortality risk for dialysis patients
treated in U.S. and in Lombardy according to age group. The
adjustment by the Cox model includes gender, renal disease,
comorbid conditions and the dialytic modality of treatment (day
30). The relative mortality risk for Lombardy ranged between
65% lower (RR 0.35) in the patients of the 25- to 44-year-old
age group to about 20% lower (RR = 0.80) in the patients over
age 65 years when compared to similar U.S. patients. When
analyzing the relative mortality risk with comorbidity adjustments
only for diabetic patients in the two registries, the difference was
smaller (RR = 0.85) and did not reach statistical significance. In
the corresponding separate analysis restricted to nondiabetic
patients, those treated in Lombardy had a significantly lower
Table 2. Relative death rates by demographic and comorbid factors
(Cox main effects model B for dialysis)
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>
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I
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mortality risk than those treated in the U.S. (RR = 0.74, P <
0.0001).
Discussion
The present study shows that the statistically adjusted mortality
risk (Cox) was significantly lower for RLDT patients than for
USRDS patients by a large magnitude of 21% for all RRT and
29% for dialysis patients. As estimated in this study, the adjusted
difference in cumulative RRT survival is 3.9 percentage points at
one year, 8.9 at two years and 12.5 at five years. The previous
study on ESRD patient survival in U.S., Europe and Japan [1] was
adjusted for age, sex and renal disease (diabetic and non-diabetic
nephropathy). The difference in five years adjusted cumulative
survival between USA and Europe was of about 8 percentage
points and that between USA and Japan 15 percentage points [1].
Data about the adjusted survival in the first years of RRT are
available between USA and Japan showing a survival difference of
17 percentage points at one year and 23 percentage points at two
years for 45- to 64-year-old dialysis patients [21, but similar data
have not been reported between USA and Europe. The current
study differs from the previous international comparisons of
ESRD patient survival [1, 2] in several ways. It considers a more
recent time period of follow-up until December 31, 1991. It used
merged individual patient records from both Registries and thus
allowed statistical analyses. Moreover, it considered the comorbid
conditions and early modality of treatment. Earlier international
comparisons have been criticized for ignoring selection factors
and attributing difference in survival to technique [11]. Therefore,
this study has markedly improved the validity of relative mortality
risk estimation between two registries.
However, there remain concerns of several potential biases that
could affect this kind of comparison: differences may exist in life
expectancy of general population, selection criteria for admission
to RRT, in access to dialysis facilities, in the registration of
ESRD-treated patients, and in the transplantation rate. As shown
above, the estimated life expectancy in the U.S. white and the
Italian general populations are comparable [4, 5]. The selection of
15—24 25—44 45—64 65—74 >75
Age, years
Fig. 4. Relative mortality risk for patients treated in Lombardy versus the
US. according to age groups. Vertical bars indicate the 95% confidence
interval. Adjustments by the Cox model include gender, renal disease,
comorbid conditions and modality of treatment (day 30).
patients is important in determining mortality rates. In 1991
Lombardy had an acceptance rate of 98.2 patients per million
population [8], one of the highest in Europe [12] (range in
acceptance rates between 40 patients per million population in the
UK, to Austria at 105 patients per million population per year),
whereas USRDS reported 160 white patients per million popula-
tion [7]. Lombardy has no apparent actual restrictions in admit-
ting patients on dialysis treatment, leaving the question unan-
swered why the U.S. has a strikingly higher acceptance rate. One
may argue that the reason lies on the differences between the
general populations; however, in 1991, the proportion of the white
elderly resident population in the U.S. [4] was not greater than
that of Lombardy (13.55% vs. 14.4%) [5]. Moreover, the propor-
tion of type 2 diabetics in the general population are similar: 4.4%
and 9.0% for U.S. residents aged respectively 45 to 54 years and
over 75 years [13], and approximately 8.2% for ages over 44 years
in Lombardy residents [14]. Therefore, only the greater estimated
annual incidence rate of type 1 diabetes in the U.S. white people
aged 0 to 18 years [13], 14.8 to 16.1 versus 6.04 per 100,000 in
Lombardy [14], may partly justify the greater proportion of
diabetics in the incident ESRD patients. The Lombardy dialysis
centers (40 out of 44 are non-profit) also cover the rural areas well
and dialysis is free of charge. It may also be possible that patients
dying during the first few weeks of RRT are underreported to
some degree. However, both the USRDS and RLDT prospec-
tively collect data about each new ESRD patient at baseline.
Moreover, in this study the evaluation of the survival was started
on day 30, partly avoiding this possible bias. When the same
analysis was replicated excluding deaths and risk period for the
first 90 days and the first 180 days, the result of comparison did
not change substantially. Therefore, the reason for the higher
acceptance rate of elderly and diabetics in U.S. possibly may be
due to different degree of hidden selection criteria or to different
survival from competing risks. Diabetic patients and patients with
atherosclerosis may be affected by coronary artery disease as well
as renal insufficiency. The U.S. higher acceptance rate of elderly
and diabetic patients may be explained in part by a lower death
rate from coronary artery disease before the onset of ESRD [15].
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Fig. 3. Cox survival curve estimates for patients on dialysis in Lombardy
and the US adjusted for age, gender, renal disease, comorbid conditions
and modality of treatment (day 30). Symbols are: (—) RLDT, N =
1296; ( ) USRDS; N = 2900. RR = 0.712; p < 0.0001.
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One may argue that a Registry with a higher acceptance rate has
a likely sicker population. The result of this study supports this
hypothesis (Table 1). Certainly, the inclusion of comorbid condi-
tions in the multivariate model reduces the selection bias. How-
ever, it does not eliminate such bias because patients of the
Registry with higher acceptance rate are more likely affected by
both the presence of comorbid conditions and greater disease
severity patterns. Moreover, it is important to note that comorbid
conditions were collected in two different ways. The USRDS Case
Severity Study collected the data by a external review of the
patient record, whereas RLDT collects comorbidity directly by the
each facility's key physician. Therefore, differences in labeling of
comorbid conditions may have occurred and efforts need to be
directed at improving the comparability of the data among
registries. Such efforts should include the development of a
common form with common definitions of important comorbid
conditions as well as indicators of their severity.
Kidney transplantation is another source of selection: it is well
known and recently documented [16—181 that patients with long
survival potential are chosen for transplantation, leaving those
with comparatively short survival prognosis on dialysis. Therefore,
in order to evaluate this possible bias, the interaction between age
and Registry was tested in the model, since the elderly patients
have a low probability to be transplanted in either the U.S. or
Lombardy. This interaction was considered both as a categorical
variable and as a continuous variable, to assess a contribution of
age on the outcome comparison by registry. The model A
multivariate analysis considered all RRT combined including
transplantation. Since U.S. patients are more likely to receive a
transplant, this analysis would tend to favor the U.S. results. The
relative risk for Lombardy patients was in fact not quite as low for
all RRT (RR = 0.79) as in the dialysis patient analysis of model
B (RR = 0.71). Overall, the patient outcomes were still markedly
and significantly better for ESRD patients of Lombardy than for
comparable patients of the U.S.
As expected, the relative risk of death between the two regis-
tries is greater in the younger patients, where a greater proportion
of censoring healthier patients for transplantation is more likely.
However, a significantly lower relative risk of death by 20%
(RR = 0.80) in Lombardy is present also among elderly patients.
Among 65- to 74-year-old patients, the relative risk estimate has a
95% confidence interval between 12 and 26%. According to
pre-treatment comorbid conditions adjustment and lack of post-
treatment USRDS negative selection due to transplantation, the
relative death risk estimation of the elderly age group may be the
most accurate.
Analyzing the mortality of the patients treated in Lombardy
and in the U.S. according to the dialytic modality of treatment
(model B), the relative risk of death between the Registries was
significantly different only in patients treated by hemodialysis who
were aged less than 60. It is well known that peritoneal dialysis in
the late I 980s was a fairly uniform prescription of treatment, with
the great majority of the patients treated by continuous ambula-
tory peritoneal dialysis with four exchanges of 2 liters per day [191.
On the other hand, the relative risk of mortality of the younger
patients on hemodialysis may he related to treatment with a wide
range of dialysis dose [201 (adequacy) levels which depend on the
length of dialysis session, blood flow, surface and type of mem-
brane, as well as reuse of dialyzers. The common use of unmod-
ified cellulose membranes [21] and of reused dialyzers [22] may
contribute to the higher mortality risk for U.S. patients on
hemodialysis, although in the U.S. the association of mortality
with reuse overall was small [22]. Therefore, the results of this
study may be explained in part by differences in the commonly
delivered hemodialysis dose [23, 24] as well as in the reuse
practice between the U.S. and the Lombardy centers. During the
1980s the reuse of dialyzers was employed by very few dialysis
centers in Lombardy.
Finally, it is important to stress that the reported results are for
the 1986 and 1987 incident cohorts. It has been reported [3] that
the death rates in the first year of therapy have been decreasing in
the U.S. since 1987 for each subsequent annual incident cohort of
ESRD patients. Unless similar improvements occurred in Lom-
bardy, comparison of more recent cohorts may show a smaller
difference in patient outcome.
Conclusions
There is evidence of a greater death rate of white U.S. than
Lombardy ESRD patients after having adjusted for age, gender,
renal disease and comorbid conditions. The death relative risk was
higher also in older patients less likely to be transplanted.
Any comparison that involves separate registries must be
interpreted with great caution. Although unmeasured differences
in patient characteristics may have played a role, the results of this
study suggest that the higher risk of death could be related to
difference in quality of hemodialysis therapy, since the differences
were significant only for hemodialysis patients. This study must be
considered as a first step for a deeper evaluation of the magnitude
of the outcome differences, with the aim to suggest reasons for
observed differences. For international studies, the development
of common standard data collection instruments are needed in all
ESRD Registries, including the recording of comorbid conditions
and hopefully also evaluating their severity.
Reprint requests to Friedrich K Port, M.D., M.S., Kidney Epidemiology
and Cost Center, 315 West Huron, Suite 240, Ann Arbor, Michigan 48103,
USA.
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